IUdR/BUdR Cell Cycle Labelling

This study has been completed.

First Received on July 24, 2002. Last Updated on January 20, 2012 History of Changes

Sponsor:	M.D. Anderson Cancer Center
Information provided by (Responsible Party):	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00042250

Purpose

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Condition	Intervention
Hematologic Malignancies	Drug: Chemotherapy for hematologic malignancy

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Resource links provided by NLM:

MedlinePlus related topics: Cancer

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Enrollment:	28
Study Start Date:	May 1992
Study Completion Date:	October 2002
Primary Completion Date:	October 2002 (Final data collection date for primary outcome measure)

Detailed Description:

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Histologic proof of one of:

AML, ALL, or AUL
MDS or CMML
CML
OR undergoing bone marrow transplantation.

Participants should be:

off therapy for at least two weeks
At least 18 years old or older
Using adequate contraception if of child-bearing capability.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00042250

Locations

United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Investigators

Study Chair:

Michael Andreeff, MD, PhD

M.D. Anderson Cancer Center

More Information

Additional Information:

M. D. Anderson Cancer Center This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00042250 History of Changes
Other Study ID Numbers:	DM91-102
Study First Received:	July 24, 2002
Last Updated:	January 20, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:

Cell Cycle Interphase
G0
G1
G2
S Phase

Additional relevant MeSH terms:

Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases

ClinicalTrials.gov processed this record on February 09, 2012